Elobixibat
ALIMENTARY TRACT AND METABOLISM
Also known as: A3309, AJG533, AZD7806, elobixibat hydrate, goofice
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Elobixibat is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2018. DrugCentral lists 2 molecular targets, including SLC10A2 and NR1H4. Recorded indications include Chronic constipation.
- Molecular targets: SLC10A2 and NR1H4 (2 listed in DrugCentral).
- Indications: Chronic constipation.
- ATC code: A06AX09 (Other drugs for constipation).
- Molecular formula: C36H45N3O7S2; molecular weight 695.89 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Chronic constipation
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Ileal sodium/bile acid cotransporter | SLC10A2 | inhibitor | IC50 9.28 |
| Bile acid receptor | NR1H4 | unknown | IC50 8.92 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2018-01-19 | PMDA | — | EA Pharma |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A06AX09 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Other drugs for constipation |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Pleurothotonus | 52.3 |
| Hepatic function abnormal | 44.0 |
| Interstitial lung disease | 32.7 |
| Pneumonia aspiration | 32.4 |
Chemical structure
| Molecular formula | C36H45N3O7S2 |
|---|---|
| Molecular weight | 695.89 g/mol |
| CAS number | 439087-18-0 |
| InChIKey | XFLQIRAKKLNXRQ-UUWRZZSWSA-N |
| PubChem CID | 9939892 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Elobixibat used for?
DrugCentral lists the following indications for Elobixibat: Chronic constipation.
How does Elobixibat work?
Its molecular targets in DrugCentral include SLC10A2 (inhibitor) and NR1H4.
When was Elobixibat first approved?
Elobixibat was first approved by the PMDA in 2018.
What is the chemical formula of Elobixibat?
Elobixibat has the molecular formula C36H45N3O7S2 and a molecular weight of 695.89 g/mol.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5277 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3039515 — compound record and bioactivity
- PubChem CID 9939892 — chemical identifiers
- DrugBank DB12486 — drug record
- FDA UNII 865UEK4EJC — substance identity
- UniProt Q12908 (SLC10A2) — target protein
- UniProt Q96RI1 (NR1H4) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.